Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

This trial aims to evaluate the efficacy, safety, and biological mechanisms of rutin combined with tislelizumab and GC(Gemcitabine and Cisplatin) in platinum-refractory muscle-invasive bladder cancer patients. Key research questions include: 1. Whether rutin regulates epigenetic mechanisms in tumor cells from platinum-refractory bladder cancer patients and modulates the tumor immune microenvironment. 2. Evaluating the safety and adverse events of the combination treatment in platinum-refractory bladder cancer patients. 3. Assessing the disease control rate in platinum-refractory bladder cance

Trial Details

NCT ID
NCT06916494
Phase
PHASE1
Sponsor
First Affiliated Hospital of Chongqing Medical University
Status
RECRUITING
Cancer Type
Muscle-Invasive Bladder Cancer
Interventions
  • Rutin
  • Gemcitabine, Cisplatin
  • Tislelizumab
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Patients with cT2-cT4N0M0 muscle-invasive bladder cancer (MIBC)
  • No response after 2 cycles of GC neoadjuvant chemotherapy
  • No prior use of systemic immunotherapy or target therapy
  • Tumor is measurable according to New response evaluation criteria in solid tumours: Revised RECIST guideline

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Muscle-Invasive Bladder Cancer Trials on Trialify →